Introduction de Theraclion sur Alternext à Paris

Back

Paris – 25 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs , today announced the listing of Theraclion, an echotherapy specialist using high-intensity focused ultrasound (HIFU) for non-invasive treatment of tumours, on Alternext in Paris. 

Founded in 2004, Theraclion is a French company that offers a totally non-invasive treatment for benign breast and thyroid tumours. Following ten years of research and development, it developed EchoPulse®, an innovative ultrasound solution harnessing echotherapy for scar-less ablation of breast and thyroid tumours. Solidly protected by 20 international patent families, EchoPulse® has already received the CE mark and now offers an effective alternative to surgery and mini-invasive techniques.

Theraclion (ticker symbol: ALTHE) was listed through the admission to trading of the 2,854,124 ordinary shares making up the company’s equity,  of 155,063 new shares created by the conversion of OCA-13 bonds and 1,000,000 new shares issued under a Global Offering .

The admission and issue price of Theraclion shares was set at €14.50 per share. Market capitalisation was around €54.5 million on the day of listing. Altogether the offering raised nearly €10.9 million.

“We are delighted to accompany Theraclion in its listing on Alternext,” said Eric Forest, Chairman and CEO of EnterNext. “This new stage in the company’s development will mean deploying its innovative technology-based solutions on international markets, and will raise Theraclion’s profile with investors,” he noted.

Theraclion CEO Stefano Vagliani added “Our successful listing gives Theraclion the resources we need to become a leading player in a world market estimated at €6 billion . We are now in a position to step up the development of our distribution network, enhance our R&D efforts and pursue the clinical trials necessary to break into the North American and Chinese markets. Our market listing will also give us greater visibility and facilitate discussions now in progress. I would like to thank all of our employees and partners, in particular Truffle Capital and our new shareholders, for their trust.”
 

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.